4//SEC Filing
Liau Gene 4
Accession 0001209191-21-017869
CIK 0001623526other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 5:00 PM ET
Size
19.1 KB
Accession
0001209191-21-017869
Insider Transaction Report
Form 4
Liau Gene
EVP Research & Preclinical Dev
Transactions
- Sale
Common Stock
2020-12-28$58.73/sh−149$8,751→ 21,351 total - Exercise/Conversion
Common Stock
2021-03-02$0.60/sh+5,195$3,117→ 26,546 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-12-28−8,000→ 88,069 totalExercise: $0.60Exp: 2028-04-02→ Common Stock (8,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2021-03-02−5,195→ 82,874 totalExercise: $0.60Exp: 2028-04-02→ Common Stock (5,195 underlying) - Exercise/Conversion
Common Stock
2020-12-28$0.60/sh+8,000$4,800→ 21,500 total - Sale
Common Stock
2021-03-02$62.46/sh−2,295$143,351→ 24,251 total - Sale
Common Stock
2021-03-02$63.52/sh−2,900$184,195→ 21,351 total - Award
Employee Stock Option (right to buy)
2021-03-02+40,800→ 40,800 totalExercise: $60.00Exp: 2031-03-01→ Common Stock (40,800 underlying)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
- [F5]The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001780082
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 5:00 PM ET
- Size
- 19.1 KB